Author(s):
Spandana B, Shashidher B, Dinesh S, Nagaraj B
Email(s):
bnrpharmacy@kakatiya.ac.in
DOI:
10.5958/0974-360X.2020.00933.6 
Address:
Spandana B, Shashidher B, Dinesh S, Nagaraj B*
University College of Pharmaceutical Sciences, Kakatiya University, Warangal – 506001 Telangana State, India.
*Corresponding Author
Published In:
Volume - 13,
Issue - 11,
Year - 2020
ABSTRACT:
The main objective of this research work was to formulate and evaluate the orodispersible tablets of eletriptan hydrobromide (EH). EH is a selective 5HT1B/1D receptor agonist used in the treatment of migraine. Formulation of EH in the form of orodispersible tablets (ODT) would facilitates the release of the drug in less time; hence it can be used in acute treatment of migraine. The EH-ODT formulations were prepared with varying concentrations of different supradisintegrants such as crosspovidone, croscarmellose sodium, and sodium starch glycolate by direct compression method. Prepared EH-ODTs were evaluated for physical parameters, drug content, disintegration time, and in vitro drug release. Other parameters such as wetting time, water absorption ratio, and drug-excipient compatibility were also evaluated. Based on the results, formulation F9 was selected as optimized formulation with disintegration time of 18 sec and cumulative percentage drug release of more than 95% in 10 min. The optimized formulations were subjected to short term stability study by storing the formulations at 40± 2ºc/75± 5% RH up to three months. The formulations F9 was found to be stable during the study. Therefore, the results confirm the ODTs of EH could be considered as an alternative for acute treatment of migraine.
Cite this article:
Spandana B, Shashidher B, Dinesh S, Nagaraj B. Eletriptan hydrobromide Orodispersible tablets: Design, Development and In vitro characterization. Research J. Pharm. and Tech. 2020; 13(11):5339-5344. doi: 10.5958/0974-360X.2020.00933.6
Cite(Electronic):
Spandana B, Shashidher B, Dinesh S, Nagaraj B. Eletriptan hydrobromide Orodispersible tablets: Design, Development and In vitro characterization. Research J. Pharm. and Tech. 2020; 13(11):5339-5344. doi: 10.5958/0974-360X.2020.00933.6 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2020-13-11-48
REFERENCES:
1. Palem CR, Narendar D, Satyanarayana G, Varsha BP. Development and optimization of Atorvastatin calcium-cyclodextrin inclusion complexed oral disintegrating tablets for enhancement of solubility, dissolution, pharmacokinetic and pharmacodynamic activity by central composite design. Int J Pharm Sci Nanotech, 2016; 9(2): 1-11.
2. Parakh SR, Gothoskar AV. A review of mouth dissolving tablet technologies. Pharma. Tech, 2003; 92-98.
3. Sastry SV, Nyshadham JR, Fix JA. Recent technological advances in oral drug delivery - A review. Pharm Sci Technology Today. 2000; 3:138–45.
4. Narendar D, Someshwar K, Arjun N, Madhusudan Rao Y. Quality by design approach for development and optimization of Quetiapine Fumarate effervescent floating matrix tablets for improved oral delivery. J Pharm Inves, 2016; 46(3):253-263.
5. Hirani JJ, Rathod DA, Vadalia KR. Orally disintegrating tablets: A review. Trop J Pharm Res. 2009; 8:161-172.
6. Narendar D and Kishan Veerabrahma. Candesartan cilexetil loaded solid lipid nanoparticles for oral delivery: characterization, pharmacokinetic and pharmacodynamic evaluation. Drug Delivery, 2016, 23 (2); 395-404.
7. FuY, Yang S, Jeong SH, Kimura S, Park K. orally fast disintegrated tablets: Development, technologies, taste masking and clinical studies. Crit Rev Ther Drug Carrier Systems, 2004; 21: 433-476.
8. Meyers GL, Battist GE, Fuisz RC. Process and apparatus making rapidly dissolving dosage units and product there form. US patent 1999.866,163.
9. Bhupendra. Formulation and evaluation of orally disintegrating tablet of Cinnarazine. J Sci tech, 2010; 5: 5-10.
10. Raghavender rao. Development of Carbmazepine fast dissolving tablets. Asian J Pharm clin res, 2010; 3(2): 40-48.
11. Ramadan NM, Current trends in Migrane prophylaxis. Headache 2007; 47: S52-S57.
12. Milton KA, Scott NR, Allen MJ, et al. Pharmacokinetics, pharmacodynamics and safety of the 5-HT1B /1D agonist elitriptan following intravenous and oral administration. J Clin Pharmacol, 2002: 42 (5) : 528-539.
13. Shah AK, LaBoy-Goral L, Scott N, et al. Pharmacokinetics and safety of oral eletriptan during different phases of the menstrual cycle in healthy volunteers. J Clin Pharmacol 2001; 41 (12): 1339-1344.
14. Narendar D, Palem CR, Reddy S, Rao YM. Pharmaceutical Development and Clinical Pharmacokinetic Evaluation of Gastroretentive Floating Matrix Tablets of Levofloxacin. Int J Pharm Sci Nanotech, 2011; 4(3): 1461-1467.
15. Narendar D, Arjun N, Karthik Yadav J, Ramesh B Amoxycillin trihydrate floating-bioadhesive drug delivery system for eradication of helicobacter pylori: preparation, in vitro and ex vivo evaluation. J Bioequ Avail, 2016; 8(3): 118-124.
16. Arun B, Arjun. N and Narendar D. Formulation and characterization of Liquid Crystalline Hydrogel of Agomelatin: In vitro and Ex vivo evaluation. J Applied Pharm Sci, 2015; 5 (9) 110-114.
17. Swetha E, Narendar D. Influence of β-cyclodextrin and hydroxypropyl-β-cyclodextrinon enhancement of solubility and dissolution of isradipine. Int J Pharm Sci Nanotech, 2017; 10(3):3752-3757.
18. Arjun N, Narendar D, Sunitha K, Harika K, Madhusudan Rao Y and Nagaraj B. Development, evaluation and influence of formulation and process variables on in vitro performance of oral elementary osmotic device of atenolol. Int J Pharm Invest, 2016; 6(4):1-9.
19. Habib W, Khankari R, Hontz J. Fast dissolving Drug Delivery Systems. Crit Rev TM Ther Drug Carr sys, 2000: 17(1); 61-72.
20. Bonadeo D, Ciccarello F, PaganoA. Process for the preparation of granulates suitable to the preparation of rapidly disintegratable mouth soluble tablets and compositions obtained thereby. US Patent 1998. 6, 316,029.